TargetMI’s Post

CHF 14 Million to advance life-saving blood purification technology: TOP 100 Swiss startup hemotune AG raises Series B2 funding. Congrats and best of success onwards to Lukas Langenegger and his team of medtech innovators! https://lnkd.in/dWQ9kGxf The investment was led by Belmondo and existing investors including VP Venture Partners, HEMEX, OCCIDENT, Zürcher Kantonalbank, and joined by EFI. About: hemotune AG is developing a revolutionary medical device for blood purification that combines cutting-edge scientific results from biomedicine and nanotechnology. It allows specific and direct removal of disease-causing substances from the blood stream of a patient. The technology targets a broad range of harmful compounds such as toxins, pathogenic organisms, or overdosed drugs. Moreover, by being more targeted, efficient, and gentler than previous blood filters, we outperform state of the art therapies and improve patient outcomes. Hemotune is a 2017 alumnus of Venture Kick and three-time laureate of the TOP 100 Swiss Startup Award. #VentureKick #SwissStartups #TOP100SSU

📣 Are you a Swiss early-stage startup or a pre-startup (planning to be incorporated soon) tackling problems related to oncology, pain treatment, or AI for health and drug development? 🌐   Then take advantage of this unique opportunity! Whether you're an emerging science-based startup or your innovation project is still in a pre-startup phase, this is your chance to shine. 🌟   Applications are now open for Swiss early-stage startups (max 3 years after incorporation) and pre-startups that aim to turn science into health solutions focusing on oncology, pain treatment, or AI for health and drug development. Swissnex and the Embassy of Switzerland in Denmark have partnered with #YScience, the official side event of Slush for Life Sciences, organized by the Helsinki Institute of Life Science (HiLIFE) at the University of Helsinki in collaboration with Orion Corporation.   🏆 The finalists will receive pitching coaching, get a Startup Pass to attend Slush, pitch in the Y Science stage and in the #Swisstech Pavilion at Slush, meet potential investors, network with experts in the fields of their solution – and compete for the 5000 EUR prize for the winner!   ➡ Apply until 23 September and check more info here:  https://lnkd.in/e_J297JF   #Startup #Innovation #OpenCall #PitchingCompetition #Pharma #PainTreatment #AIforHealth #DrugDevelopment #Startups #Slush

🚀 April's early-stage funding wrapup reveals intriguing trends and triumphs! Healthtech shines bright while the UK maintains its crown! 💰💡 📊 In April, Europe saw €1.4bn invested across 312 pre-seed, seed, and Series A rounds, a tad lower than March's figures. The UK led the pack in funding, with France and Germany following suit. 🇬🇧🇫🇷🇩🇪 💼 B2B SaaS, Climate tech, and Healthtech stole the spotlight, reaping in €345m, €333m, and €315m respectively. Notably, Healthtech experienced a surge, with drug discovery and biotech at the forefront, attracting €138m and €135m respectively. 💉🧬 🤝 Y Combinator, Antler, and Bpifrance emerged as top investors, fueling the startup ecosystem's growth. 👏 🌟 Highlighting some remarkable rounds. In the UK, Biofidelity secured €22m, accelerating genomic technologies for faster test results. Meanwhile, Infinitopes in Oxford raised £12.8m, revolutionizing cancer vaccines through precision immunomics antigen discovery. In France, EXO Biologics secured €9m in equity and €7m in grants, pioneering exosome-based therapies for critical diseases. 🌱 🔍 Dive deeper into April's standout rounds and pivotal insights at Sifted.  #fundingtrends #healthtechadvancements #europeanstartups #healthcareinnovation #venturecapital #techinvestments 🌐

Lamark Biotech, a T-Angel startup is redefining the accessibility of modern medicine for under-developed areas. Most vaccines, especially for insulin, eye degeneration, and lung cancer need refrigeration and stability. Vaibhav Bhatia, CEO at Lamark Biotech talks about how the company has dedicated itself to making these medicines refrigerator-independent so that it can reach the deepest parts of the country! Watch Vaibhav talk about T-Hub's support at multiple levels from legality and due diligence to end-to-end assistance in being investment-ready! T-Hub is empowering founders and their startups. Watch here: https://bit.ly/49EMIAK #THubFounderTalks #InnovateWithThub #InnovationEcosystem

✨ 𝗠𝗮𝗷𝗼𝗿 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗳𝗼𝗿 𝗡𝗫𝗜 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀: 𝗦𝗲𝗰𝘂𝗿𝗶𝗻𝗴 𝟯.𝟱 𝗠 𝗖𝗛𝗙 𝗣𝗿𝗲-𝗦𝗲𝗲𝗱 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 💰 𝑊ℎ𝑎𝑡 𝑑𝑜𝑒𝑠 𝑎 3.5 𝑀 𝐶𝐻𝐹 𝑝𝑟𝑒-𝑠𝑒𝑒𝑑 𝑓𝑢𝑛𝑑𝑖𝑛𝑔 𝑚𝑒𝑎𝑛 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑓𝑢𝑡𝑢𝑟𝑒 𝑜𝑓 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑣𝑒 𝑖𝑚𝑚𝑢𝑛𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑖𝑒𝑠? 🥇 𝗣𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗜𝗺𝗽𝗮𝗰𝘁 𝗼𝗻 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗖𝗮𝗿𝗲 💉 NXI Therapeutics AG, a 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗕𝗮𝘀𝗲𝗹 spin-off, is harnessing coronin 1 modulation to develop groundbreaking treatments for autoimmune diseases and transplant medicine. Their approach promises safer, more effective therapies by selectively targeting immune responses without compromising the body's defense against infections and cancer. 🏛 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆'𝘀 𝗖𝗿𝘂𝗰𝗶𝗮𝗹 𝗥𝗼𝗹𝗲 🚀 The University of Basel has been instrumental in supporting NXI Therapeutics through its Propelling grant and strategic partnerships. This collaboration underscores the university’s commitment to fostering innovation and bridging the gap between academic research and real-world applications, fulfilling at the highest level the "third mission" of a modern academic institution and the mission of the Innovation Office: 𝘱𝘳𝘰𝘱𝘦𝘭𝘭𝘪𝘯𝘨 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘰𝘳𝘴 𝘵𝘰 𝘢𝘤𝘩𝘪𝘦𝘷𝘦 𝘪𝘮𝘱𝘢𝘤𝘵! 🌟 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝗮 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗶𝗻𝗴 𝗖𝗹𝗶𝗺𝗮𝘁𝗲 ⛈ In a difficult period for startup fundraising, securing 3.5 million CHF from prominent investors like 𝗝𝗙𝗚 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻, 𝗕𝗮𝘀𝗲𝗟𝗮𝘂𝗻𝗰𝗵, 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗞𝗶𝗰𝗸, and 𝗞𝗶𝗰𝗸𝗳𝘂𝗻𝗱 is a remarkable achievement. It highlights the critical need for continued support and investment in early-stage ventures to drive transformative healthcare solutions. At the Innovation Office of the University of Basel, we are proud to celebrate this significant achievement, which exemplifies our commitment to nurturing groundbreaking innovations and supporting startups in their journey from academia to impactful real-world applications. Looking forward for even bigger successes to come - 𝗵𝘂𝗴𝗲 𝗰𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗡𝗫𝗜 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘁𝗲𝗮𝗺! We will share more insights about this incredible startup venture very soon - so follow-us and stay tuned! You can find a few info and the official press release below. #InnovationEcosystem #LifeSciences #Biotech #StartupFunding #UniversityOfBasel #Immunotherapy #HealthcareInnovation

#fundingalert 💼Company: En Carta Diagnostics 💰Funding: €1.5 Million ⚡Round: Pre-Seed 👥Investors: CentraleSupélec Venture Diagnostics that enhance patient care, regardless of location. En Carta Diagnostics is a synthetic-biology biotech company that employs patented #technologies to decentralise highly dependable molecular diagnostic solutions. The proceeds will be utilised by En Carta to create a diagnostic device that is capable of independently detecting Lyme disease within minutes. Additionally, the funding will facilitate the #development of a robust ecosystem and the execution of its go-to-market strategy. Guillaume Horréard, Cédric Curtil, Margot Karlikow, PhD Read more - https://lnkd.in/g75Khj7x To share your startup story write us on - contact@startuprise.co.uk #EnCartaDiagnostics #moleculardiagnostic #biotechcompany #funding #fundingnews #startup #startupnews #startuprise

⏳ 8 weeks of intense hybrid training are almost over for the #startups of the #BiotechBootcamp2023. Now, soon it is time to pitch, persuade, and prosper! And we invite YOU to participate! 🎧 Listen to the Bootcamp #startup pitches and learn about the next emerging #biotechnology breakthroughs from the very start at the Bootcamp Demo Day! 📅 on December 7th, 9am - 3pm 📍 Conference room "Ellipse" at IZB - Innovation and Startup Center for Biotechnology, #Munich-Martinsried, Germany Agenda and registration here: ➡️ https://lnkd.in/eG5xu3Br Hurry, as 🪑🪑🪑 seats are limited on site! Together with dozens of mentors and coaches, SmiLe Incubator and #BioM equipped aspiring #biotech #entrepreneurs with the knowledge, skills and industry connections required to transform a breakthrough biotech idea into a successful scalable business. Now they're eager to shine and scoop up awards! 9 teams are currently busy preparing for the glorious final Demo Day, to present the results of their hard work: 👉 AmyCureBio – blocking amyloids for Parkinson's treatment. 👉 EmulsiBiotech – natural platforms for drugformulation and delivery. 👉 ENDOLEASEsystems – an innovative high precision drug delivery system. 👉 factorize.bio – learning the language of undruggable disease proteins. 👉 Genicity – bringing cell therapy within reach. 👉 RaidoGene – Seeing is believing: visualizing cell and gene therapies. 👉 ReactiveOxygenTherapeutics (ROT) – prodrugs utilizing oxidative stress in the fight against autoimmune diseases and science cancer. 👉 RevoBITs – revolutionizing bioprinting, Bit by Bit. 👉 RiboRUS – mapping ribonucleotides genome-wide. All experts who contributed to the bootcamp are invited, as well as selected early stage #investors and #BusinessAngels and the regional startup and #biotech network.   If you participate on-site, benefit from great networking opportunities and mingling with the experts. And vote for your favorite biotechnology team to receive the 🏆 #RocheAudienceAward! We cordially thank our sponsors and supporters: Merck Gruppe, Roche and the European Commission! #StartaBiotechBusiness #biotechinnovation #BusinessAngel #VC #venturecapital #investment #investor #financing

Meet Plasmid.AI at the Startup Showcase! This week, we’re excited to feature Plasmid.AI, a dynamic Canadian AI startup co-founded by Santiago Plata Salazar, Ayalinch Jonathan, Kris Shivkumar and Lauren Altomare, originating from iGEM Toronto 2024. 🚀What They Do: Plasmid.AI is on a mission to expedite phage preclinical discovery to combat antibiotic resistance. Their proprietary model will utilize the power of large language models supplemented with biophysical simulations, allowing for the reduction of time and resources required for pharmaceuticals to discover and conduct preclinical trials on phage candidates by minimizing repetitive in vitro testing. By seamlessly integrating AI with current biology techniques, Plasmid.AI aims to accelerate the preclinical discovery phase of developing phage therapies and is paving the way for next generation tools to fight antibiotic resistance. Check out their website at plasmidai.com and watch them live at the iGEM Grand Jamboree from October 23-26, 2024! 🎫Get your jamboree ticket now - jamboree.igem.org #igem #igemstartups #synbio #Biofounders #bioentrepreneurship #igem2024

Move for mental health: let’s invest!

🌟#StartupSpotlight: Get to know our amazing residents at our high-tech incubator! 🌟This week, we're shining the spotlight on Lifelight Health GmbH! ❗ Did you know that targeted drug delivery systems offer a promising approach to improving treatment outcomes? Unlike, for example, traditional chemotherapy, which can have systemic side effects, delivering medication directly to the affected site, enhances effectiveness while reducing damage to healthy tissue - exactly the goal of Lifelight Health! Lifelight Health is developing innovative implantable medical devices for the targeted release of biologicals and small molecules without the need for injection. The system is based on a novel linker system that enables an actively controlled, precise and rapid release of approved drugs. This kind of localized therapy allows highly effective treatment of hard-to-reach targets, such as brain tumours, while minimizing side effects for patients. Curious about who's in our current batch? Check out our website and learn more about our startups & incubation programme! https://lnkd.in/eEnDKGsv Simon Blazy Oliver Plettenburg  #StartupSpotlight #BioIntelligence #HighTechIncubator #Biotech #Lifesciences #InnovationHub #IncubatorLife #StartupEcosystem #Entrepreneurship #StartupCommunity #StartupJourney #StartupLife